Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Debt to Equity (2016 - 2026)

Ironwood Pharmaceuticals' Debt to Equity history spans 12 years, with the latest figure at -$2.23 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 74.78% to -$2.23 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.23, a 74.78% decrease, with the full-year FY2025 number at -$2.23, down 74.78% from a year prior.
  • Debt to Equity hit -$2.23 in Q4 2025 for Ironwood Pharmaceuticals, down from -$2.21 in the prior quarter.
  • Over the last five years, Debt to Equity for IRWD hit a ceiling of $0.37 in Q4 2023 and a floor of -$2.23 in Q4 2025.
  • Historically, Debt to Equity has averaged -$1.0 across 5 years, with a median of -$1.28 in 2024.
  • The widest YoY moves for Debt to Equity: up 23.53% in 2024, down 446.6% in 2024.
  • Tracing IRWD's Debt to Equity over 5 years: stood at $0.19 in 2021, then increased by 20.75% to $0.23 in 2022, then soared by 58.29% to $0.37 in 2023, then tumbled by 446.6% to -$1.28 in 2024, then tumbled by 74.78% to -$2.23 in 2025.
  • Business Quant data shows Debt to Equity for IRWD at -$2.23 in Q4 2025, -$2.21 in Q3 2025, and -$1.9 in Q2 2025.